metallothionein and Hearing-Loss--Sensorineural

Megalin has been proposed as an endocytic receptor for aminoglycosides as well as estrogen and androgen. We aimed to investigate the otoprotective effects of antiandrogens (flutamide, FM) on kanamycin (KM)-induced hearing loss in rats. Rats were divided into four groups. The KM group was administered KM (20 mg/kg/day) for 5 days, while the FM group received FM (15 mg/kg/day) for 10 days. In the KM + FM group, KM and FM (15 mg/kg/day) were simultaneously injected for 5 days and then FM was injected for 5 days. Auditory brainstem responses were measured. Western blotting and/or quantitative reverse transcriptase-polymerase chain reaction were performed for megalin, cytochrome P450 1A1 (Cyp1a1), Cyp1b1, metallothionein 1A (MT1A), MT2A, tumor necrosis factor (TNF)-α, caspase 3, and cleaved caspase 3. The FM + KM group showed attenuated auditory thresholds when compared with the KM group at 4, 8, 16, and 32 kHz (all

Topics: Androgen Receptor Antagonists; Animals; Anti-Bacterial Agents; Auditory Threshold; Cochlea; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Evoked Potentials, Auditory, Brain Stem; Flutamide; Gene Expression; Hearing Loss, Sensorineural; Kanamycin; Low Density Lipoprotein Receptor-Related Protein-2; Male; Metallothionein; Protective Agents; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tumor Necrosis Factor-alpha